https://www.selleckchem.com/pr....oducts/pluripotin-sc
01 for all domains) compared with the nonablation group. At the 1-year follow-up, greater improvement in the AFEQT scores was noted in the ablation group, even after adjusting for clinically relevant factors (+20.0 ± 1.2,+14.2 ± 0.9, respectively; p0.001). Notably, 306 (28%) patients met the criteria for symptom underrecognition, which was associated with the nonuse of catheter ablation during follow-up (odds ratio 0.41; confidence interval, 0.28-0.60; p0.001). Underrecognition of AF symptom burden was frequently noted an